vs
Side-by-side financial comparison of MacKenzie Realty Capital, Inc. (MKZR) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $4.6M, roughly 2.0× MacKenzie Realty Capital, Inc.). Protalix BioTherapeutics, Inc. runs the higher net margin — -60.3% vs -97.4%, a 37.1% gap on every dollar of revenue. On growth, MacKenzie Realty Capital, Inc. posted the faster year-over-year revenue change (-42.8% vs -49.9%). Over the past eight quarters, MacKenzie Realty Capital, Inc.'s revenue compounded faster (6.1% CAGR vs -6.7%).
MacKenzie Realty Capital, Inc. is a U.S.-based real estate investment firm focused on acquiring, owning, and managing a diversified portfolio of income-generating commercial and residential real estate assets. It targets properties in high-growth regional markets across the U.S. to deliver consistent long-term returns to its investors.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
MKZR vs PLX — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.6M | $9.1M |
| Net Profit | $-4.5M | $-5.5M |
| Gross Margin | — | 49.4% |
| Operating Margin | -102.5% | -51.1% |
| Net Margin | -97.4% | -60.3% |
| Revenue YoY | -42.8% | -49.9% |
| Net Profit YoY | -0.4% | -184.8% |
| EPS (diluted) | $-2.97 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.6M | $9.1M | ||
| Q3 25 | $4.5M | $17.9M | ||
| Q2 25 | $4.8M | $15.7M | ||
| Q1 25 | $4.3M | $10.1M | ||
| Q4 24 | $8.0M | $18.2M | ||
| Q3 24 | $5.0M | $18.0M | ||
| Q2 24 | $4.5M | $13.5M | ||
| Q1 24 | $4.1M | — |
| Q4 25 | $-4.5M | $-5.5M | ||
| Q3 25 | $-3.0M | $2.4M | ||
| Q2 25 | $-6.0M | $164.0K | ||
| Q1 25 | $-6.1M | $-3.6M | ||
| Q4 24 | $-4.5M | $6.5M | ||
| Q3 24 | $-7.4M | $3.2M | ||
| Q2 24 | $-2.5M | $-2.2M | ||
| Q1 24 | $-2.9M | — |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
| Q4 25 | -102.5% | -51.1% | ||
| Q3 25 | -76.8% | 11.9% | ||
| Q2 25 | -117.3% | 7.5% | ||
| Q1 25 | -136.4% | -41.0% | ||
| Q4 24 | -56.7% | 39.6% | ||
| Q3 24 | -150.3% | 22.2% | ||
| Q2 24 | -58.1% | -18.0% | ||
| Q1 24 | -65.6% | — |
| Q4 25 | -97.4% | -60.3% | ||
| Q3 25 | -67.1% | 13.2% | ||
| Q2 25 | -125.1% | 1.0% | ||
| Q1 25 | -142.6% | -35.8% | ||
| Q4 24 | -55.5% | 35.6% | ||
| Q3 24 | -149.6% | 18.0% | ||
| Q2 24 | -55.6% | -16.4% | ||
| Q1 24 | -72.3% | — |
| Q4 25 | $-2.97 | $-0.06 | ||
| Q3 25 | $-2.20 | $0.03 | ||
| Q2 25 | $-8.16 | $0.00 | ||
| Q1 25 | $-0.47 | $-0.05 | ||
| Q4 24 | $-3.93 | $0.10 | ||
| Q3 24 | $-6.10 | $0.03 | ||
| Q2 24 | $-9.20 | $-0.03 | ||
| Q1 24 | $-0.26 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.3M | $14.7M |
| Total DebtLower is stronger | $145.6M | — |
| Stockholders' EquityBook value | $51.8M | $48.2M |
| Total Assets | $238.1M | $82.3M |
| Debt / EquityLower = less leverage | 2.81× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.3M | $14.7M | ||
| Q3 25 | $4.9M | $13.6M | ||
| Q2 25 | $3.6M | $17.9M | ||
| Q1 25 | $5.1M | $19.5M | ||
| Q4 24 | $6.5M | $19.8M | ||
| Q3 24 | $10.7M | $27.4M | ||
| Q2 24 | $11.9M | $23.4M | ||
| Q1 24 | $15.5M | — |
| Q4 25 | $145.6M | — | ||
| Q3 25 | $142.7M | — | ||
| Q2 25 | $135.3M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $14.7M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $117.3M | — | ||
| Q1 24 | — | — |
| Q4 25 | $51.8M | $48.2M | ||
| Q3 25 | $56.7M | $52.9M | ||
| Q2 25 | $59.9M | $49.9M | ||
| Q1 25 | $66.7M | $45.2M | ||
| Q4 24 | $68.3M | $43.2M | ||
| Q3 24 | $73.4M | $32.4M | ||
| Q2 24 | $82.4M | $28.6M | ||
| Q1 24 | $86.3M | — |
| Q4 25 | $238.1M | $82.3M | ||
| Q3 25 | $241.7M | $82.3M | ||
| Q2 25 | $236.0M | $78.5M | ||
| Q1 25 | $237.1M | $73.9M | ||
| Q4 24 | $236.4M | $73.4M | ||
| Q3 24 | $243.5M | $61.6M | ||
| Q2 24 | $233.1M | $91.5M | ||
| Q1 24 | $226.1M | — |
| Q4 25 | 2.81× | — | ||
| Q3 25 | 2.52× | — | ||
| Q2 25 | 2.26× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.22× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.6M | $2.0M |
| Free Cash FlowOCF − Capex | — | $1.6M |
| FCF MarginFCF / Revenue | — | 17.8% |
| Capex IntensityCapex / Revenue | — | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.6M | $2.0M | ||
| Q3 25 | $-2.0M | $-3.7M | ||
| Q2 25 | $-1.7M | $-5.2M | ||
| Q1 25 | $-2.6M | $-5.1M | ||
| Q4 24 | $1.9M | $4.0M | ||
| Q3 24 | $644.4K | $4.1M | ||
| Q2 24 | $-595.5K | $-3.6M | ||
| Q1 24 | $743.3K | — |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q1 24 | — | — |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MKZR
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
